Loading…
4 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| GM Pharmaceuticals | Pharma | 33.6% | 81st pct | 110 |
| Alpha | (unclassified) | 28.3% | 78th pct | 1208 |
| Sports Saiens Georgia | Fitness & Wellness | 1.0% | 47th pct | 30 |
| PSP Pharma | Pharma | 6.8% | 30th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | PSP Pharma | GM Pharmaceuticals | Sports Saiens Georgia | Alpha |
|---|---|---|---|---|
| Margins | ||||
| Gross Margin | 22.5% | 66.0% | 96.9% | 62.3% |
| EBITDA Margin | 6.8% | 33.6% | 1.0% | 28.3% |
| EBITDAR | 57,112 | 62,063 | 10 | 171 |
| EBITDAR Margin | 6.8% | 33.6% | 1.0% | 28.3% |
| EBIT Margin | 4.4% | 29.4% | -19.5% | 25.4% |
| Net Profit Margin | 3.4% | 32.1% | -20.9% | 27.9% |
| Operating Expense % of Sales | 15.7% | 32.4% | 95.8% | 34.0% |
| Returns | ||||
| Return on Assets (ROA) | 4.3% | 22.5% | -8.0% | 12.9% |
| Return on Equity (ROE) | 8.9% | 23.9% | -8.3% | 13.4% |
| ROIC [EBIT / Invested Capital] | 8.9% | 27.0% | -7.7% | 22.1% |
| Leverage & debt balances | ||||
| Debt-to-Assets | 16.9% | 0.3% | 1.0% | 0.0% |
| Debt-to-Equity | 0.35x | 0.00x | 0.01x | 0.00x |
| Debt-to-EBITDA | 1.97x | 0.01x | 2.55x | 0.00x |
| Equity-to-Assets | 48.6% | 94.2% | 96.1% | 96.0% |
| Net Debt | 91,853 | -46,609 | 22 | -560 |
| Cash & Equivalents | 20,687 | 47,348 | 3 | 560 |
| Total Debt | 112,540 | 738 | 25 | N/A |
| Liquidity & working capital | ||||
| Current Ratio | 1.58x | 13.46x | 1.29x | 13.92x |
| Quick Ratio | 0.41x | 8.26x | 1.29x | 13.92x |
| Cash Ratio | 0.08x | 3.15x | 0.04x | 10.68x |
| Total Current Assets | 392,371 | 202,180 | 97 | 731 |
| Total Current Liabilities | 248,714 | 15,021 | 75 | 52 |
| Inventory | 291,297 | 78,109 | N/A | N/A |
| Trade Receivables | 76,883 | 67,384 | 4 | 162 |
| Trade Payables | 192,919 | 8,373 | 75 | 45 |
| Net Working Capital | 143,657 | 187,159 | 22 | 678 |
| Net Working Capital % of Revenue | 17.0% | 101.2% | 2.3% | 112.3% |
| Trade Working Capital | 175,261 | 137,121 | -71 | 117 |
| Trade Working Capital % of Revenue | 20.7% | 74.2% | -7.3% | 19.4% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A |
| Turnover & efficiency | ||||
| Inventory Turnover | 2.25x | 0.81x | N/A | N/A |
| Days Inventory Outstanding (DIO) | 162.3 | 453.2 | N/A | N/A |
| Receivables Turnover | 10.99x | 2.74x | 240.94x | 3.72x |
| Days Sales Outstanding (DSO) | 33.2 | 133.0 | 1.5 | 98.0 |
| Payables Turnover | 3.40x | 7.51x | 0.41x | 5.04x |
| Days Payable Outstanding (DPO) | 107.5 | 48.6 | 899.0 | 72.4 |
| Cash Conversion Cycle | 88.0 days | 537.6 days | -897.4 days | 25.7 days |
| Asset Turnover | 1.27x | 0.70x | 0.38x | 0.46x |
| Cash flow & dividends | ||||
| Operating Cash Flow | 20,831 | 10,288 | 1 | 174 |
| Free Cash Flow (OCF − Capex proxy) | 19,867 | 5,119 | 13 | 174 |
| Cash Conversion (OCF / EBITDA) | 36.5% | 16.6% | 14.0% | 102.0% |
| Dividends Declared | 31,235 | 0 | N/A | N/A |
| Dividend Payout Ratio | 107.8% | 0.0% | N/A | N/A |